Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib combined with prednisone, thalidomide, and danazol for adult myelofibrosis
ChiCTR1900025219Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ruxolitinib, prednisone, thalidomide and danazol in myelofibrosis (MF), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: overall response rate, improvement in cytopenia and 2 more. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on ChiCTR1900025219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025219.